1.Treatments for COVID-19: What helps, what doesn't, and what's in the pipeline: Harvard Health Publishing – Harvard Medical School, Updated April 24, 2020 Published: March, 2020.

2. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395, 497–506 (2020).

3. Zirui Tay M, Poh CM, Rénia L, MacAry PA, Ng LPA. The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews; published online 28 April 2020

4. Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence . Int J Antimicrob Agents. Available online 19 March 2020, 105948

5. Qing-Lei Zeng, et all: Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients. The Journal of Infectious Diseases, 04/2020

6. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949. doi: 10.1016/j. ijantimicag.2020.105949. [Epub ahead of print]

7. Choudhary R, Sharma AK, Choudhary R. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020 Apr 22:100684. doi: 10.1016/j. nmni.2020.100684. [Epub ahead of print]